Research Topics
Species | Matthew EllisSummaryAffiliation: Washington University School of Medicine Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Predicting endocrine therapy responsiveness in breast cancerCynthia X Ma
Section of Medical Oncology, Division of Oncology, Department of Internal Medicine, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, Missouri 63110, USA
Oncology (Williston Park) 23:133-42. 2009....
The genomic landscape of breast cancer as a therapeutic roadmapMatthew J Ellis
Division of Medical Oncology, Section of Breast Oncology, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
Cancer Discov 3:27-34. 2013..In this Prospective, we summarize some of the headline conclusions from 6 recent breast cancer "omics profiling" articles in Nature, with an emphasis on the implications for systemic therapy...- Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intMatthew J Ellis
Siteman Cancer Center, Washington University in St Louis, 660 South Euclid Avenue, St Louis, MO 63110, USA
J Clin Oncol 29:2342-9. 2011..To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations... - Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancerCesar G Sanchez
Department of Hematology Oncology, School of Medicine, Pontificia Universidad Catolica de Chile, Lira 85, 4th Floor, Santiago 8330023, Chile
Breast Cancer Res 13:R21. 2011.... - Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trialMatthew J Ellis
Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63119, USA
Breast Cancer Res Treat 116:371-8. 2009..Expression of aromatase by malignant breast epithelial cells and/or the surrounding stroma implies local estrogen production that could influence the outcome of endocrine therapy for breast cancer... - Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerMatthew J Ellis
Department of Medicine, Washington University School of Medicine, St Louis, MO 63119, USA
Breast Cancer Res Treat 119:379-90. 2010..Nonetheless, as with other recent studies, a favorable interaction between PIK3CA KD mutation and prognosis was detected. The mechanism for the favorable prognostic impact of PIK3CA mutation status therefore remains unexplained... - Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized studyMatthew J Ellis
Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
JAMA 302:774-80. 2009..Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells to low-dose estradiol therapy... 
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancerFarrokh Dehdashti
Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology, St Louis, MO 63110, USA
Breast Cancer Res Treat 113:509-17. 2009....- Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trialsYu Tao
Siteman Cancer Center and Washington University in St. Louis, Campus Box 8506, 660 South Euclid Avenue, St. Louis, MO 63110, USA
J Steroid Biochem Mol Biol 95:91-5. 2005.... - Femara and the future: tailoring treatment and combination therapies with FemaraMatthew Ellis
Medical Oncology, Washington University, 660 Euclid Ave, Campus Box 8056, St Louis, MO 63110, USA
Breast Cancer Res Treat 105:105-15. 2007..Microarray gene profiling studies, designed to detect letrozole-responsive targets, are currently under way to understand how the use of the drug can be tailored more efficiently to specific patient needs... - Overcoming endocrine therapy resistance by signal transduction inhibitionMatthew Ellis
Siteman Cancer Center, Washington University, St Louis, Missouri 63110, USA
Oncologist 9:20-6. 2004..With a number of phase III clinical trials now under way, major advances in the endocrine treatment of advanced disease are possible... - PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancerRobert J Crowder
Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA
Cancer Res 69:3955-62. 2009..Our results suggest that PI3K inhibitors should target both p110alpha and p110beta catalytic subunits, whether wild-type or mutant, and be combined with endocrine therapy for maximal efficacy when treating ER(+) breast cancer... - The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancersP Kelly Marcom
Siteman Comprehensive Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8056, St Louis, MO, USA
Breast Cancer Res Treat 102:43-9. 2007..The efficacy of the aromatase inhibitor letrozole in combination with trastuzumab was therefore tested in a Phase 2 study... - A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancerYing Liu
Division of Health Behavior Research, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63108, USA
Breast Cancer Res Treat 124:835-44. 2010..Educating early-stage breast cancer patients about their actual risk could result in more realistic recurrence-risk perceptions, and increasing social support could help alleviate anxiety associated with exaggerated risk perceptions... - Therapy related acute myeloid leukemia in breast cancer survivors, a population-based studyMike G Martin
Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8007, Saint Louis, MO 63110, USA
Breast Cancer Res Treat 118:593-8. 2009..This association maybe explained by either greater chemotherapy exposure or an interaction between therapy and genetic predisposition... - Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristicsMatthew J Ellis
Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63119, USA
J Natl Cancer Inst 100:1380-8. 2008.... - Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression statusMatthew J Ellis
Duke University Comprehensive Cancer Center, Campus Box 8056, 660 South Euclid, Durham, NC 27710, USA
Cancer Res 63:6523-31. 2003.... - Letrozole in the neoadjuvant setting: the P024 trialMatthew J Ellis
Medical Oncology, Washington University, Campus Box 8056, 660 Euclid Ave, St Louis, MO 63110, USA
Breast Cancer Res Treat 105:33-43. 2007..0009). Thus, neoadjuvant letrozole is safe and superior to tamoxifen in the treatment of postmenopausal women with HR+ locally advanced breast cancer... - A luminal breast cancer genome atlas: progress and barriersMatthew J Ellis
Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63119, USA
J Steroid Biochem Mol Biol 106:125-9. 2007.... - Neoadjuvant endocrine therapy as a drug development strategyMatthew J Ellis
Washington University School of Medicine, St Louis, Missouri, USA
Clin Cancer Res 10:391S-5S. 2004..However, the optimal clinical investigative approaches, analytical techniques, and appropriate surrogate end points have yet to be identified and are the subject of several ongoing or planned clinical studies... - Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current dataMatthew J Ellis
Siteman Comprehensive Cancer Center and Washington University School of Medicine, St Louis, MO 63110, USA
Curr Med Res Opin 22:2479-87. 2006..This review will compare the current available efficacy, safety, and cost-effectiveness data for AIs in the initial adjuvant and switch adjuvant settings... - Neoadjuvant endocrine therapy for locally advanced breast cancerCynthia X Ma
Department of Oncology, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
Semin Oncol 33:650-6. 2006..In this review, we outline the rationale for preoperative endocrine therapy, and consider predictive models for endocrine therapy responsiveness in this setting... - Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozoleMatthew J Ellis
Siteman Comprehensive Cancer Center, Washington University School of Medicine, Campus Box 8056, 660 S Euclid Ave, St Louis, MO 63110, USA
J Clin Oncol 24:3019-25. 2006.... - Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathwayRobert J Crowder
Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, St Louis, Missouri, USA
Breast Cancer Res 7:212-4. 2005.... - Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapyMatthew J Ellis
Washington University School of Medicine, Section of Medical Oncology and Breast Cancer Program, St Louis, Missouri, USA
Ann Surg Oncol 11:9S-17S. 2004..Ongoing investigations are examining gene expression profile changes associated with neoadjuvant endocrine therapy, as well as inhibitors of growth factor signaling that may modulate tamoxifen resistance... - Successful targeting of ErbB2 receptors-is PTEN the key?Robert J Crowder
Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, Campus Box 8056, 660 South Euclid Avenue, St Louis, MO 63110, USA
Cancer Cell 6:103-4. 2004..Resistance to trastuzumab occurs when PTEN function is lost, suggesting that PTEN activation is a critical component of the therapeutic effect... - Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialRebecca Aft
Department of Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
Lancet Oncol 11:421-8. 2010..The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells (DTCs) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer... - Neoadjuvant endocrine therapy for breast cancerJane S Chawla
Division of Oncology, Department of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA
Surg Oncol Clin N Am 19:627-38. 2010.... - High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancerNicola Napoli
Division of Bone and Mineral Diseases at Washington University School of Medicine, St Louis, Missouri, USA
Breast J 16:609-16. 2010..Future studies may be needed to establish the contribution of low vitamin D, if any, on the prevalence of musculoskeletal pains in women on AIs... - "I'm pregnant and I have breast cancer"Michael J Naughton
Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
BMC Cancer 7:93. 2007..There is general consensus that both surgery and chemotherapy are relatively safe after the first trimester of pregnancy. It is generally agreed that therapeutic radiation, if necessary, should be delayed until completion of pregnancy... - Genome remodelling in a basal-like breast cancer metastasis and xenograftLi Ding
The Genome Center at Washington University, St Louis, Missouri 63108, USA
Nature 464:999-1005. 2010..The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour... - Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignanciesPaula M Fracasso
Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
Cancer Chemother Pharmacol 63:451-8. 2009..To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of weekly docosahexaenoic acid-paclitaxel (DHA-paclitaxel), a taxane fatty acid conjugate...
Research Grants
- Novel Biomarkers for Aromatase Inhibitor TherapyMatthew Ellis; Fiscal Year: 2007..abstract_text> ..
- Novel Biomarkers for Aromatase Inhibitor TherapyMatthew J Ellis; Fiscal Year: 2010....